BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8866821)

  • 1. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.
    Miners JO; Coulter S; Tukey RH; Veronese ME; Birkett DJ
    Biochem Pharmacol; 1996 Apr; 51(8):1003-8. PubMed ID: 8866821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.
    Rodrigues AD; Kukulka MJ; Roberts EM; Ouellet D; Rodgers TR
    Drug Metab Dispos; 1996 Jan; 24(1):126-36. PubMed ID: 8825200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K; Konishi T; Nishikawa H; Kitamura S
    Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
    McKillop D; Wild MJ; Butters CJ; Simcock C
    Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
    Heyn H; White RB; Stevens JC
    Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
    Baldwin SJ; Clarke SE; Chenery RJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
    Rifkind AB; Lee C; Chang TK; Waxman DJ
    Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
    Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.
    Ko JW; Desta Z; Flockhart DA
    Drug Metab Dispos; 1998 Aug; 26(8):775-8. PubMed ID: 9698292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation.
    Tracy TS; Marra C; Wrighton SA; Gonzalez FJ; Korzekwa KR
    Eur J Clin Pharmacol; 1997; 52(4):293-8. PubMed ID: 9248768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine.
    Tugnait M; Hawes EM; McKay G; Eichelbaum M; Midha KK
    Chem Biol Interact; 1999 Apr; 118(2):171-89. PubMed ID: 10359460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.